Results 181 to 190 of about 4,805 (202)

Selinexor-associated hyponatremia: single-center, real-world data

Kidney International, 2020
Jaya Kala, Omar Mamlouk, Kenar D. Jhaveri   +2 more
openaire   +2 more sources

Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies

Gynecologic Oncology, 2020
S N Han, Craig C Hofmeister
exaly  

E3 ubiquitin ligase ASB8 promotes selinexor-induced proteasomal degradation of XPO1

Biomedicine and Pharmacotherapy, 2023
Bert Kwanten, Dirk Daelemans
exaly  

Dexamethasone/selinexor/triamcinolone interaction

Reactions Weekly, 2021
openaire   +1 more source

Drug resistance biomarker ABCC4 of selinexor and immune feature in multiple myeloma

International Immunopharmacology, 2022
Yang Liang, Yu-Jun Dai, Xue-Ping Li
exaly  

Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial

Lancet Haematology,the, 2020
Nagesh Kalakonda, Marie France Madeleine Maerevoet, Federica Cavallo   +2 more
exaly  

FoxO-1 contributes to the efficacy of the combination of the XPO1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models

Biochemical Pharmacology, 2018
Cristina Corno, Michelandrea De Cesare, Emilio Ciusani   +2 more
exaly  

Selinexor (KTP-330) - a selective inhibitor of nuclear export (SINE): anti-tumor activity in diffuse large B-cell lymphoma (DLBCL)

Expert Opinion on Investigational Drugs, 2020
John G Kuruvilla
exaly  

Selinexor. Exportin-1 (XPO1) inhibitor, Oncolytic

Drugs of the Future, 2014
null Riaz, W., null Burke, N., null Mahipal, A.   +2 more
openaire   +1 more source

Selinexor

Reactions Weekly
openaire   +1 more source